Single-cell Omics Market Size, Share & Trends Analysis Report By Product Type (Single-cell Genomics, Single-cell Transcriptomics), By Application (Oncology, Neurology), By End-User, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global single-cell omics market size was valued at USD 1.40 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 16.1% from 2023 to 2030.  The market is mainly driven by technological advancements in single-cell analysis & increase in large-scale genomics studies leveraging single-cell RNA sequencing. In addition, the rapidly growing biotechnology and biopharmaceutical industries and increasing demand for biologics are other factors propelling market growth forward. Also, the surge in the prevalence of life-threatening conditions has propelled the demand for personalized medicine.

COVID-19 had a positive impact on the market as this technology was in high demand to investigate the viral-host interactions, immune response, and the effects of the virus on various cell types. In addition, technology has been used in developing precision diagnostics by studying specific markers. The technology is projected to witness more growth opportunities owing to the rising burden of chronic diseases and rising demand for novel therapeutics.

The increasing prevalence of cancer and rising applications of single-cell analysis in studying cancer progression is projected to fuel the demand for omics technology in understanding the cell biology of cancer. According to the Canadian government, cancer is the leading cause of death in the country. Furthermore, according to the Canadian Cancer Society, about 2 in 5 Canadians are expected to develop cancer during their lifetime. The single-cell omics analysis offers a brief identification of various immune subsets at higher resolution and offers an opportunity to understand overall tumor progression. In addition, individual cellular omics involve analysis of individual cells that facilitate accurate diagnosis and monitoring of treatment efficacy.

New advances in single-cell technologies are facilitating the opportunity to discern biological insights within individual cells. Moreover, the newer single-cell platforms have fueled cellular separation and analysis capabilities that have created higher interest among researchers, particularly in the arena of individual cellular genomics. Thus, the evolving demand for novel single-cell analysis platforms is pushing manufacturers to launch innovative products in the market. For instance, in June 2021 Cellenion and SCIENION launched cellenCHIP 384 for single-cell omics sample preparation. With this launch, the company expanded its automated capabilities and high throughput workflows.

Moreover, the increasing importance of single-cell omics and their evolving application in cell biology and personalized medicine have garnered momentum for this technology. In addition, rising interest in single-cell analysis research and rising funding programs are projected to support market growth. For instance, in November 2022, the Texas A&M University System received a grant of USD 1.19 million from NIH to leverage single-cell sequencing technology. This project aims to bolster cancer diagnosis, treatment, and prevention.

Furthermore, the other remarkable trend in this discipline is the advent of multi-omics. This approach improves data efficiency and quality through the study of multiple analytes concurrently with techniques such as splitting samples, combined analysis, or altering one class of analytes into another. An example of such a multi-omics method is transcriptomes, which work by sequencing (CITE-seq by Illumina) and cellular indexing of epitopes. This method combines the sequencing and capturing of RNA inside the cell by utilizing barcoded antibodies that interact with the epitopes on the cell surface.

Product Type Insights

The single-cell genomics segment was the leading revenue contributor for the market in 2022 and held 45.8% of the market share. Factors such as increasing demand from a wide range of end-users, potential clinical applications of single-cell genomics platforms, and technological advancements are the major factors driving segment growth. New technologies like microfluidics, high-throughput sequencing platforms, and droplet-based methods enabled researchers to study cellular heterogeneity at unprecedented resolution.

Moreover, efforts from market players to accelerate their single-cell level sequencing capabilities are another factor supporting segment uptake. For instance, in February 2023 Singular Genomics Systems, Inc. announced the launch of Max Read kits for single cell applications on the C4 sequencing platform of a company. This newly launched product will increase the output and decrease the overall cost of experiments.

The growing interest in metabolomics, rising funding from government and non-government organizations to accelerate metabolomics research, and rising applications in disease research are some of the factors driving the single-cell metabolomics segment. Moreover, the potential of advances in metabolomics and integration of single-cell metabolomics in cancer diagnostics owing to its higher sensitivity of detecting cancer cells are likely to create high momentum for the segment in the coming years.

Application Insights

The oncology segment led the single-cell omics market in 2022 with a share of 55.1% and the segment is also projected to exhibit the highest growth rate during the 2023-2030 period. The rising burden of cancer globally, rapid evolution in single-cell analysis techniques, and rising adoption of omics-based tools to study cancer progression are projected to support a high market share of the segment. According to Globocan 2020, China reported around 4.57 million cancer cases with around 3 million deaths. Thus, the higher burden of cancer has significantly augmented the demand for novel approaches to reduce and manage the global burden. The omics-based tools remain extremely significant to study tumor progression and analyze tumor cell heterogeneity that can aid effective diagnosis and foster treatment outcomes.

Furthermore, the rising adoption of personalized medicine for the treatment of a variety of cancers has contributed to segment uptake as single-cell genomics becomes increasingly important in precision medicine to foster diagnosis and overall monitoring of disease. Market players such as Mission Bio; CYTENA; Illumina; and others offer comprehensive solutions for different cancers.

The immunology segment is projected to hold the second-fastest CAGR of 15.9% during the forecast period. Ongoing research studies, supportive government legislation, and robust demand for advanced therapeutics have driven the segment to a certain extent. In addition, the rising adoption of single-cell omics in developing various immunotherapies and therapeutic antibodies has propelled segment uptake.

End-User Insights.

The academic and research organizations segment dominated the end-user segment of the market with a 42.8% market share in 2022. The rising usage of technology on college campuses, increasing research efforts to develop novel modeling tools, and rising research studies by various research institutes to explore diverse applications of cellular biology are projected to drive segment growth. Moreover, researchers are exploring numerous applications of single-cell technologies across various fields, including transcriptomics, genomics, proteomics, epigenomics, and metabolomics. For instance, in March 2023, Schmidt Futures granted USD 550 million to a new research facility focused on developing single-cell proteomics technologies.

Increasing efforts by pharmaceutical and biotech companies to develop advanced targeted therapeutics, increasing R&D investments, and rising efforts from these companies to facilitate drug discovery is anticipated to drive segmental growth. In addition, rising collaboration between companies to develop novel technologies is further contributing to segment expansion. For instance, in February 2023 Ultima Genomics, Inc partnered with 10x Genomics to enable the integration of chromium single cellular applications on ultima sequencers.

Regional Insights

North America accounted for the largest share of the global market and accounted for 46.37% of the market in 2022. The presence of several market players and various developments made by them are some of the key factors driving regional growth. Moreover, the presence of advanced healthcare and rising R&D activities for the development of novel technologies are other factors propelling the regional market. In addition, supportive government legislation, the rising importance of cellular therapies, and the growing trend for precision medicine are further supporting the regional market. For instance, the U.S. has implemented the precision medicine initiative to improve health and treat diseases.

Asia Pacific is estimated to grow at the fastest rate of 17.8% CAGR from 2023 to 2030. Factors such as the increasing burden of target disease and rising demand for advanced therapeutics are anticipated to drive the single-cell omics market in the region. The rising interest of market players to capture untapped market potential and rising investments by them in the region are facilitating the region’s market growth. Moreover, growing agreements between companies to strengthen their market avenues is another potential factor driving the regional market. For instance, in December 2021, Mission Bio and SequMed signed an agreement that allowed Mission Bio to leverage its offerings in China.

Key Companies & Market Share Insights

Several major companies are vying for a higher market share in the very competitive and fragmented single-cell omics industry. Major key companies are undertaking strategic activities like mergers, acquisitions, and alliances to elevate their market position. For instance, in April 2023, Flugent Genetics launched Mission Bio, Inc. platform to broaden the accessibility of single cells multi-omics for clinical research and drug development. This will bolster the drug development capability of Fulgent Genetics. Some prominent players in the global single-cell omics market include:

• Danaher Corporation

• CYTENA GmbH

• 10x Genomics

• BD

• CELLENION

• PerkinElmer Inc.

• ANGLE plc

• Illumina, Inc.

• Bio-Rad Laboratories, Inc.

• Mission Bio

• Standard BioTools Inc.

Recent Developments

• In February 2023, BD introduced a new tool for single-cell multi-omics analysis. It allows researchers to conduct high-throughput studies without compromising sample integrity, potentially accelerating the pace of discovery across a variety of fields.

• In June 2021, SCIENION and Cellenion launched cellenCHIP 384 for single-cell omics sample preparation, available as a consumable in the new cellenCHIP 384 - 3'RNA-seq Kit for scalable, nanoliter volume library creation of single cells.

Single-cell Omics Market Report Scope

Global Single-cell Omics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global single-cell omics market report based on product type, application, end-user, and region.

• Product Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Single-Cell Genomics

  • Single-Cell Transcriptomics

  • Single-Cell Proteomics

  • Single-Cell Metabolomics

• Application Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology

  • Cell Biology

  • Neurology

  • Immunology

• End-User Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical & Biotechnology Companies

  • Academic and Research Organizations

  • Hospital and Diagnostic Laboratories

  • Others

• Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • The U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait